BioPlus Acquisition Common Stock

The latest common stock for BIOS is $140M as of June 2023. That compares with $230M in the prior-year period — down 41.1% year over year. Investors often review this figure alongside BioPlus Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, BIOS's common stock moved from $230M to $140M — a 41.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioPlus Acquisition's operating scale or balance-sheet position.

A common stock figure of $140M for BIOS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BIOS's common stock ($140M), review year-over-year change from $230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.